PressAugust 6, 2024 Elaine Elisabetsky, PhD, Member of Jaguar Health’s Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia
PressAugust 2, 2024 MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
PressAugust 2, 2024 Tryptamine Therapeutics Limited Appoints David Castle to Its Scientific Advisory Board
PressAugust 1, 2024 Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
PressJuly 31, 2024 Revitalist Lifestyle and Wellness CEO Kathryn A. Walker to Speak at The AANA Annual Congress on Psychedelics in Anesthesia
PressJuly 31, 2024 Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
PressJuly 31, 2024 Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
PressJuly 30, 2024 Incannex Healthcare : Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL 42X Form 8 K
PressJuly 30, 2024 PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
PressJuly 26, 2024 Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
PressJuly 25, 2024 Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
PressJuly 24, 2024 Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
